drugset / Trial / NCT00104364

A Study of MK0731 in Patients With Advanced Solid Tumors (0731-002)(COMPLETED)

NCT00104364 ↗

Phase 1 Completed 30 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to study MK0731 in patients with recurrent or non-responsive solid tumors, or cancers for which standard therapy does not exist. This is an early phase trial and some specific protocol information is proprietary and not publicly available at this time. (Full information is available to trial participants).

Timeline

Start
2005-05
Primary completion
2008-01
Completion
2008-01

Drugs

EvaluationDrugModalityDoseRoute
Subject MK0731 Unknown 6 mg/m2 Intravenous
Subject MK0731 Unknown 17 mg/m2 Intravenous
Subject MK0731 Unknown 48 mg/m2 Intravenous

Indications